Patents by Inventor Edward Pham
Edward Pham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240095454Abstract: Techniques are provided for using context tags in named-entity recognition (NER) models. In one particular aspect, a method is provided that includes receiving an utterance, generating embeddings for words of the utterance, generating a regular expression and gazetteer feature vector for the utterance, generating a context tag distribution feature vector for the utterance, concatenating or interpolating the embeddings with the regular expression and gazetteer feature vector and the context tag distribution feature vector to generate a set of feature vectors, generating an encoded form of the utterance based on the set of feature vectors, generating log-probabilities based on the encoded form of the utterance, and identifying one or more constraints for the utterance.Type: ApplicationFiled: November 28, 2023Publication date: March 21, 2024Applicant: Oracle International CorporationInventors: Duy Vu, Tuyen Quang Pham, Cong Duy Vu Hoang, Srinivasa Phani Kumar Gadde, Thanh Long Duong, Mark Edward Johnson, Vishal Vishnoi
-
Publication number: 20230072073Abstract: Methods of inhibiting a respiratory virus, (i.e., a virus associated with a respiratory condition, e.g., influenza A, influenza B, RSV, etc.) in a sample are provided. Aspects of the methods include contacting a sample comprising viral RNA (vRNA) having a target motif with an effective amount of an agent that specifically binds the target motif to inhibit the respiratory virus. Also provided are methods of treating or preventing respiratory virus infection in a subject. Also provided are compounds and pharmaceutical compositions comprising an oligonucleotide sequence complementary to a target vRNA region that find use in the subject methods.Type: ApplicationFiled: August 1, 2022Publication date: March 9, 2023Inventors: Jeffrey S. Glenn, Rachel Hagey Saluti, Edward A. Pham
-
Publication number: 20220347263Abstract: Methods and compositions are provided for reducing virus titer and eliminating virus-infected cells from an individual.Type: ApplicationFiled: June 9, 2020Publication date: November 3, 2022Inventors: Jeffrey S. Glenn, Edward A. Pham, Anming Xiong
-
Publication number: 20220243198Abstract: Methods of inhibiting influenza A virus in a sample are provided. Aspects of the methods include contacting a sample comprising viral RNA (vRNA) having a PSL2 motif with an effective amount of an agent that specifically binds the PSL2 motif to inhibit the influenza A virus. Also provided are methods of treating or preventing influenza A virus infection in a subject. Also provided are methods for screening a candidate agent for the ability to inhibit influenza A virus in a cell, the method comprising: contacting a sample with a candidate agent; and determining whether the candidate agent specifically binds to the PSL2 motif of vRNA. Also provided are compounds and pharmaceutical compositions comprising an oligonucleotide sequence complementary to a PB2 vRNA region that find use in the subject methods.Type: ApplicationFiled: April 8, 2022Publication date: August 4, 2022Inventors: Jeffrey S. Glenn, Rachel Hagey Saluti, Edward A. Pham
-
Patent number: 11339392Abstract: Methods of inhibiting influenza A virus in a sample are provided. Aspects of the methods include contacting a sample comprising viral RNA (vRNA) having a PSL2 motif with an effective amount of an agent that specifically binds the PSL2 motif to inhibit the influenza A virus. Also provided are methods of treating or preventing influenza A virus infection in a subject. Also provided are methods for screening a candidate agent for the ability to inhibit influenza A virus in a cell, the method comprising: contacting a sample with a candidate agent; and determining whether the candidate agent specifically binds to the PSL2 motif of vRNA. Also provided are compounds and pharmaceutical compositions comprising an oligonucleotide sequence complementary to a PB2 vRNA region that find use in the subject methods.Type: GrantFiled: February 14, 2020Date of Patent: May 24, 2022Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Jeffrey S. Glenn, Rachel Hagey Saluti, Edward A. Pham
-
Publication number: 20220153711Abstract: Compounds and methods are provided for inhibiting a PI4-kinase Methods of treating a pathogen infection and methods of treating cancer are also provided. The PI4-kinase inhibitor can be a compound that is a 5-aryl or heteroaryl-thiazole, e.g., as described herein. In certain embodiments, the PI4-kinase inhibitor is a substituted 2-amino-5-phenylthiazole or substituted 2-amino-5-pyridylthiazole compound. In some embodiments, the compounds have broad spectrum anti-infective activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of treating a subject for cancer using a PI4-kinase inhibitor. Aspects of the methods include inhibiting PI4-kinase in a cancer cell to reduce cellular proliferation.Type: ApplicationFiled: March 19, 2020Publication date: May 19, 2022Inventors: Jeffrey S. Glenn, Mark Smith, Edward A. PHAM, Kaustabh BASU, Stephen STABLER
-
Publication number: 20220062243Abstract: Methods of treating a subject for cancer using a PI4-kinase inhibitor are provided. Also provided are methods of inhibiting PI4-kinase in a cancer cell to reduce cellular proliferation. The PI4-kinase inhibitor can be a compound that is a 5-aryl or heteroaryl-thiazole, e.g., as described herein. In certain embodiments, the PI4-kinase inhibitor is a substituted 2-amino-5-phenylthiazole or substituted 2-amino-5-pyridylthiazole compound. The subject compounds may be formulated or provided to a subject in combination with one or more additional anti-cancer agents. Use of PI4-kinase inhibitors in methods of reducing cellular proliferation and methods of treatment is provided in a variety of cancer cells and cancer subjects.Type: ApplicationFiled: January 9, 2020Publication date: March 3, 2022Inventors: Jeffrey S. GLENN, Mark SMITH, Edward PHAM
-
Publication number: 20210052553Abstract: Disclosed herein are methods for use of clemizole for the treatment of a subject in need thereof. Uses include methods of treating inflammatory conditions. Uses also include methods of treating non-alcoholic steatohepatitis in a subject.Type: ApplicationFiled: May 7, 2020Publication date: February 25, 2021Inventors: Jeffrey S. Glenn, Edward A. Pham
-
Publication number: 20200239880Abstract: Methods of inhibiting influenza A virus in a sample are provided. Aspects of the methods include contacting a sample comprising viral RNA (vRNA) having a PSL2 motif with an effective amount of an agent that specifically binds the PSL2 motif to inhibit the influenza A virus. Also provided are methods of treating or preventing influenza A virus infection in a subject. Also provided are methods for screening a candidate agent for the ability to inhibit influenza A virus in a cell, the method comprising: contacting a sample with a candidate agent; and determining whether the candidate agent specifically binds to the PSL2 motif of vRNA. Also provided are compounds and pharmaceutical compositions comprising an oligonucleotide sequence complementary to a PB2 vRNA region that find use in the subject methods.Type: ApplicationFiled: February 14, 2020Publication date: July 30, 2020Inventors: Jeffrey S. Glenn, Rachel Hagey Saluti, Edward A. Pham
-
Patent number: 10688083Abstract: Disclosed herein are methods for use of R-chloroquine or clemizole or combinations of R-chloroquine and clemizole for the treatment of a subject in need thereof. Uses include methods of treating inflammatory? conditions, treating liver cancer or reducing the risk of developing liver cancer in a subject. Uses also include methods of treating non-alcoholic steatohepatitis in a subject.Type: GrantFiled: June 30, 2016Date of Patent: June 23, 2020Assignee: Eiger Group International, Inc.Inventors: Jeffrey S. Glenn, Edward A. Pham
-
Patent number: 10597658Abstract: Methods of inhibiting influenza A virus in a sample are provided. Aspects of the methods include contacting a sample comprising viral RNA (vRNA) having a PSL2 motif with an effective amount of an agent that specifically binds the PSL2 motif to inhibit the influenza A virus. Also provided are methods of treating or preventing influenza A virus infection in a subject. Also provided are methods for screening a candidate agent for the ability to inhibit influenza A virus in a cell, the method comprising: contacting a sample with a candidate agent; and determining whether the candidate agent specifically binds to the PSL2 motif of vRNA. Also provided are compounds and pharmaceutical compositions comprising an oligonucleotide sequence complementary to a PB2 vRNA region that find use in the subject methods.Type: GrantFiled: March 1, 2017Date of Patent: March 24, 2020Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Jeffrey S. Glenn, Rachel Hagey, Edward Pham
-
Publication number: 20190136242Abstract: Methods of inhibiting influenza A virus in a sample are provided. Aspects of the methods include contacting a sample comprising viral RNA (vRNA) having a PSL2 motif with an effective amount of an agent that specifically binds the PSL2 motif to inhibit the influenza A virus. Also provided are methods of treating or preventing influenza A virus infection in a subject. Also provided are methods for screening a candidate agent for the ability to inhibit influenza A virus in a cell, the method comprising: contacting a sample with a candidate agent; and determining whether the candidate agent specifically binds to the PSL2 motif of vRNA. Also provided are compounds and pharmaceutical compositions comprising an oligonucleotide sequence complementary to a PB2 vRNA region that find use in the subject methods.Type: ApplicationFiled: March 1, 2017Publication date: May 9, 2019Inventors: Jeffrey S. Glenn, Rachel Hagey, Edward Pham
-
Publication number: 20180200228Abstract: Disclosed herein are methods for use of R-chloroquine or clemizole or combinations of R-chloroquine and clemizole for the treatment of a subject in need thereof. Uses include methods of treating inflammatory? conditions, treating liver cancer or reducing the risk of developing liver cancer in a subject. Uses also include methods of treating non-alcoholic steatohepatitis in a subject.Type: ApplicationFiled: June 30, 2016Publication date: July 19, 2018Inventors: Jeffrey S. GLENN, Edward A. PHAM
-
Publication number: 20160113919Abstract: This disclosure provides a method of treating a subject infected with a mycobacteria of the M. tuberculosis complex or infected with an atypical mycobacterium. Aspects of the method include administering to a subject in need thereof a therapeutically effective amount of an enantiomerically pure (R)-chloroquine agent. The (R)-chloroquine agent may be an analog or derivate of chloroquine having a particular stereochemistry at the position located alpha to the amino-quinoline core of the chloroquine agent. Also provided are methods of inhibiting mycobacteria of the M. tuberculosis complex or other atypical mycobacteria in a cell. Kits and pharmaceutical compositions for practicing the subject methods are also provided.Type: ApplicationFiled: October 20, 2015Publication date: April 28, 2016Inventors: Niaz Banaei, Jeffrey S. Glenn, Rajiv Lochan Gaur, Tran Van, Gary K. Schoolnik, Edward Pham
-
Publication number: 20110288023Abstract: The invention provides modified Transferrin (Tf) molecules and conjugates of the Tf molecules with a therapeutic agent. The invention also provides methods of treating cancer wherein the therapeutic agents are chemotherapeutic agents. The modified Tf molecules improve the delivery of the conjugated agent to a target tissue. In some embodiments, the modified Tf molecule has a mutation which decreases the release of bound iron from a Tf complex. The complex can also contain, for instance, a carbonate, oxalate, or other anion to stabilize the Tf iron complex.Type: ApplicationFiled: December 6, 2010Publication date: November 24, 2011Applicants: The Regents of the University of California Office of Technology Transfer, Office of Technology Transfer, University of VermontInventors: Daniel T. Kamei, Bert J. Lao, Wen-Lin P. Tsai, Foad Mashayekhi, Edward A. Pham, Anne B. Mason
-
Publication number: 20090181048Abstract: The present invention provides transferrin (Tf) conjugates of anti-cancer agents with increased cellular association and increased cellular internalization. The present invention also provides methods of treating cancer comprising administration of a Tf conjugate with increased cellular association to a subject with cancer. The present invention additionally provides methods of making, as well as screening for, Tf conjugates with increased cellular association or cellular internalization. The present invention also provides Tf conjugates with increased cellular association and internalization for delivering nucleic acids to cancer cells.Type: ApplicationFiled: June 6, 2008Publication date: July 16, 2009Applicant: The Regents of the University of CaliforniaInventors: Daniel T. Kamei, Bert J. Lao, Wen-Lin P. Tsai, Foad Mashayekhi, Edward A. Pham, Anne B. Mason